Skip to main content

PDS Biotechnology Corporation (PDSB)

NASDAQ: PDSB · IEX Real-Time Price · USD
12.11
-0.22 (-1.78%)
After-hours:Oct 15, 2021 7:54 PM EDT
12.33
-1.27 (-9.34%)
At close: Oct 15, 4:00 PM
Market Cap362.72M
Revenue (ttm)n/a
Net Income (ttm)-11.57M
Shares Out23.16M
EPS (ttm)-0.53
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,136,886
Open13.75
Previous Close13.60
Day's Range11.96 - 13.75
52-Week Range1.87 - 17.85
Beta2.00
AnalystsStrong Buy
Price Target19.71 (+59.9%)
Est. Earnings DateNov 10, 2021

About PDSB

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treat...

IndustryBiotechnology
CEOFrank Bedu-Addo
Employees15
Stock ExchangeNASDAQ
Ticker SymbolPDSB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for PDSB stock is "Strong Buy." The 12-month stock price forecast is 19.71, which is an increase of 59.85% from the latest price.

Price Target
$19.71
(59.85% upside)
Analyst Consensus: Strong Buy

News

PDS Biotechnology Announces Conference Call and Webcast to Present Third-Quarter 2021 Financial Results

FLORHAM PARK, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propri...

2 days ago - GlobeNewsWire

PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-1...

FLORHAM PARK, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propri...

1 week ago - GlobeNewsWire

PDS Biotechnology to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propr...

3 weeks ago - GlobeNewsWire

PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination ...

No dose limiting toxicities observed in initial group of 12 patients No dose limiting toxicities observed in initial group of 12 patients

3 weeks ago - GlobeNewsWire

PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propr...

1 month ago - GlobeNewsWire

Best Penny Stocks To Buy In 2021? 5 That Turned $2,500 Into $26,000

Were these penny stocks on your list this year? The post Best Penny Stocks To Buy In 2021?

Other symbols:AMCBBIGPMTS
1 month ago - PennyStocks

PDS Biotechnology to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

FLORHAM PARK, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propr...

1 month ago - GlobeNewsWire

PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference

FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propr...

1 month ago - GlobeNewsWire

PDS Biotech Provides Business Update and Reports Second Quarter 2021 Financial Results

FLORHAM PARK, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propri...

2 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...

New York, New York--(Newsfile Corp. - July 12, 2021) - Levi & Korsinsky announces it has commenced an investigation of PDS Biotechnology Corporation (NASDAQ: PDSB) concerning possible breaches of fiduci...

3 months ago - Newsfile Corp

PDS Biotechnology Joins Russell Microcap® Index

FLORHAM PARK, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propri...

3 months ago - GlobeNewsWire

PDS Biotechnology Corporation Announces Closing of Approximately $52 Million Public Offering and Full Exercise of Und...

FLORHAM PARK, N.J., June 17, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing a pipeline of...

3 months ago - GlobeNewsWire

PDS Biotech Announces Proposed Offering of Common Stock

FLORHAM PARK, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing novel cancer therap...

4 months ago - GlobeNewsWire

PDS Biotechnology Announces Oncology Research and Development Day

FLORHAM PARK, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage cancer immunotherapy company developing novel cancer therapies based on the Company's...

4 months ago - GlobeNewsWire

Why PDSB Shares Are Trading Higher Today

PDS Biotechnology Corp (NASDAQ:PDSB) shares are trading higher by 13.3% at $10.65 Tuesday morning after the company highlighted the release of interim data for PDS0101 in an NCI-led Phase 2 clinical stu...

4 months ago - Benzinga

CORRECTING AND REPLACING -- PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Stu...

Tumor reduction was observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve advanced cancer patients and 58% (7 of 12) of HPV16-positive relapsed or refractory advan...

4 months ago - GlobeNewsWire

PDS Biotech's Lead Versamune Program Achieves Overall Tumor Reduction of 67% In HPV16 Positive Cancer Patients

PDS Biotechnology Corporation (NASDAQ: PDSB) has announced interim data from the Phase 2 trial led by the National Cancer Institute (NCI) evaluating PDS0101 (Versamune-HPV16) in combination with two inv...

4 months ago - Benzinga

PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at A...

Tumor reduction was observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve advanced cancer patients and 58% (7 of 12) of HPV16-positive relapsed or refractory advan...

4 months ago - GlobeNewsWire

PDS Biotechnology Expands VERSATILE-002 study of PDS0101 and KEYTRUDA® in Advanced Head and Neck Cancer to Include Pa...

FLORHAM PARK, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccin...

4 months ago - GlobeNewsWire

PDS Biotech to Host Oncology R&D Day on June 16, 2021

FLORHAM PARK, N.J., June 01, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propri...

4 months ago - GlobeNewsWire

PDS Biotechnology Establishes Partnership With Head and Neck Cancer Alliance

Strategic partnership offers both organizations a way to share information about emerging treatment options with clinicians and patients battling HPV-attributed head and neck cancer Strategic partnershi...

4 months ago - GlobeNewsWire

Implied Volatility Surging for PDS Biotechnology (PDSB) Stock Options

Investors need to pay close attention to PDS Biotechnology (PDSB) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

PDS Biotech to Host Company Conference Call Following Oral Presentation of PDS0101 Data at 2021 ASCO Annual Meeting

FLORHAM PARK, N.J., May 24, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprie...

4 months ago - GlobeNewsWire

Oppenheimer Has 5 Sizzling Biotech Stocks to Buy Now Trading Under $10

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other symbols:INFICASIISRSVRA
4 months ago - 24/7 Wall Street

NetScientific hails the potential of investee company's cancer immunotherapy

NetScientific PLC (LON:NSCI) said an investee company will share additional data that will underline the potential efficacy of a breakthrough cancer immunotherapy. PDS Biotechnology Corporation (NASDAQ:...

4 months ago - Proactive Investors